The abstract is read at the publisher; the summary is JClub's.
AML874, a selective CDK8/CDK19 inhibitor, disrupts Mediator-dependent transcription and shows subtype-specific sensitivity in FLT3-mutated AML, with strong synergy to venetoclax.
- Why it matters: AML remains lethal despite advances, and new targeted vulnerabilities are needed; this work searches broadly across genetically diverse primary samples for actionable transcriptional dependencies.
- What they did: A high-throughput screen tested 10,000 small molecules in 56 genetically diverse primary AML samples, clustering hits into CCCs; integrated pharmacology and CRISPR-Cas9 implicated the Mediator complex and identified AML874 as CDK8/CDK19-selective.
- The result: FLT3-mutated AML is linked to increased sensitivity to AML874, and CDK8 inhibition synergizes with venetoclax in AML cell lines and patient-derived xenograft models, enhancing in vivo anti-leukemic activity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.